Marker Therapeutics, Inc. MRKR
- MT-601 — Non-Hodgkin Lymphoma Phase 1
- MT-601 — Pancreatic Cancer Preclinical
- MT-401-OTS — Acute Myeloid Leukemia Phase 1
- MT-401-OTS — Myelodysplastic Syndrome Phase 1
NY-ESO-1 (1 companies · 4 programs)
Companies with an active program directed at NY-ESO-1.